Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Metformin: multi-faceted protection against cancer.

Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B, Menendez JA.

Oncotarget. 2011 Dec;2(12):896-917. Review.

2.

Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.

Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA.

Cell Cycle. 2010 Nov 15;9(22):4461-8. Epub 2010 Nov 15.

PMID:
21088486
3.

Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205.

Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Quirantes R, Segura-Carretero A, Micol V, Joven J, Bosch-Barrera J, Del Barco S, Martin-Castillo B, Vellon L, Menendez JA.

Cell Cycle. 2012 Mar 15;11(6):1235-46. doi: 10.4161/cc.11.6.19665. Epub 2012 Mar 15.

PMID:
22356767
4.

Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions.

Vazquez-Martin A, López-Bonetc E, Cufí S, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA.

Drug Resist Updat. 2011 Aug-Oct;14(4-5):212-23. doi: 10.1016/j.drup.2011.04.003. Epub 2011 May 19.

5.

Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.

Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S, Sarkar FH.

Cancer Prev Res (Phila). 2012 Mar;5(3):355-64. doi: 10.1158/1940-6207.CAPR-11-0299. Epub 2011 Nov 15.

6.

Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status.

Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA.

Cell Cycle. 2010 Sep 15;9(18):3807-14. Epub 2010 Sep 25.

PMID:
20890129
7.

Metformin: a rising star to fight the epithelial mesenchymal transition in oncology.

Barrière G, Tartary M, Rigaud M.

Anticancer Agents Med Chem. 2013 Feb;13(2):333-40. Review.

PMID:
22721394
8.

Metformin is synthetically lethal with glucose withdrawal in cancer cells.

Menendez JA, Oliveras-Ferraros C, Cufí S, Corominas-Faja B, Joven J, Martin-Castillo B, Vazquez-Martin A.

Cell Cycle. 2012 Aug 1;11(15):2782-92. doi: 10.4161/cc.20948. Epub 2012 Aug 1.

PMID:
22809961
9.

Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4.

Zhang J, Shen C, Wang L, Ma Q, Xia P, Qi M, Yang M, Han B.

Biochem Biophys Res Commun. 2014 Sep 26;452(3):746-52. doi: 10.1016/j.bbrc.2014.08.154. Epub 2014 Sep 6.

PMID:
25201727
10.

Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.

Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA.

Cell Cycle. 2010 Mar 15;9(6):1057-64. Epub 2010 Mar 15. Review.

PMID:
20305377
11.

Metformin: taking away the candy for cancer?

Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG.

Eur J Cancer. 2010 Sep;46(13):2369-80. doi: 10.1016/j.ejca.2010.06.012. Epub 2010 Jul 23. Review.

PMID:
20656475
12.

Emerging roles for modulation of microRNA signatures in cancer chemoprevention.

Neelakandan K, Babu P, Nair S.

Curr Cancer Drug Targets. 2012 Jul;12(6):716-40. Review.

PMID:
22515522
13.

Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.

Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, Martin-Castillo B, Menendez JA.

Oncotarget. 2012 Apr;3(4):395-8.

14.

Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy.

Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH.

Curr Protoc Pharmacol. 2013 Jun;Chapter 14:Unit 14.25. doi: 10.1002/0471141755.ph1425s61. Review.

15.

Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined.

Lee H, Park HJ, Park CS, Oh ET, Choi BH, Williams B, Lee CK, Song CW.

PLoS One. 2014 Feb 5;9(2):e87979. doi: 10.1371/journal.pone.0087979. eCollection 2014.

16.

Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current.

Gritti M, Würth R, Angelini M, Barbieri F, Peretti M, Pizzi E, Pattarozzi A, Carra E, Sirito R, Daga A, Curmi PM, Mazzanti M, Florio T.

Oncotarget. 2014 Nov 30;5(22):11252-68.

17.

Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell.

Nishi M, Akutsu H, Kudoh A, Kimura H, Yamamoto N, Umezawa A, Lee SW, Ryo A.

Oncotarget. 2014 Sep 30;5(18):8665-80.

18.

Metformin: risk-benefit profile with a focus on cancer.

Provinciali N, Lazzeroni M, Cazzaniga M, Gorlero F, Dunn BK, DeCensi A.

Expert Opin Drug Saf. 2015 Oct;14(10):1573-85. doi: 10.1517/14740338.2015.1084289. Epub 2015 Sep 11. Review.

PMID:
26359221
19.

Repurposing old drugs to chemoprevention: the case of metformin.

Heckman-Stoddard BM, Gandini S, Puntoni M, Dunn BK, DeCensi A, Szabo E.

Semin Oncol. 2016 Feb;43(1):123-33. doi: 10.1053/j.seminoncol.2015.09.009. Epub 2015 Sep 8. Review.

PMID:
26970131
20.

Metformin and prostate cancer stem cells: a novel therapeutic target.

Mayer MJ, Klotz LH, Venkateswaran V.

Prostate Cancer Prostatic Dis. 2015 Dec;18(4):303-9. doi: 10.1038/pcan.2015.35. Epub 2015 Jul 28. Review.

PMID:
26215782
Items per page

Supplemental Content

Write to the Help Desk